Compare Morgan Stanley (MS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Tango Therapeutics Inc. — how do they compare? Morgan Stanley trades at $181.6 (market cap $293.13B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Morgan Stanley is far larger — about 78.2× Tango Therapeutics Inc.'s market cap, and Morgan Stanley pays a 2.46% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 90 Days and Tango Therapeutics Inc. for 0 Days on average.
| MS | TNGX | |
|---|---|---|
Market Cap | $293.13B | $3.75B |
Volume | 8,184,975 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $228.42 | $32.90 |
52-Week Low | $154.37 | $7.50 |
Typical Hold Time | 90 Days | 0 Days |
Enterprise Value | $658.86B | $2.77B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $190.02, showing stability with no recent price change. The stock exhibits a bearish technical signal but maintains strong fundamentals, with revenue growing to $66.0B in 2025 and net income reaching $16.9B. Recent earnings have consistently beaten expectations, and analyst consensus remains bullish with a $229.25 price target. The company highlights growth in wealth management and AI financing as key drivers.
The outlook for MS is positive, supported by earnings momentum and strategic growth areas, though risks include volatile cash flows and high debt levels. Investment opportunity lies in its above-sector profitability and analyst upside, but investors should monitor macroeconomic sensitivity and competitive pressures in financial services.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
